Page 584 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

562 PART IV Specific Malignancies in the Small Animal Patient

303. Koshkina NV, Kleinerman ES: Aerosol gemcitabine inhibits the 325. Thapa P, Nikam D, Das T, et al.: Clinical efficacy and safety com-
growth of primary osteosarcoma and osteosarcoma lung metastases, parison of 177Lu-EDTMP with 153Sm-EDTMP on an equi-
Int J Cancer 116:458–463, 2005. dose basis in patients with painful skeletal metastases, J Nucl Med
VetBooks.ir 304. Khanna C, Anderson PM, Hasz DE, et al.: Interleukin-2 liposome 326. Lipton A: New therapeutic agents for the treatment of bone dis-
56:1513–1519, 2015.
inhalation therapy is safe and effective for dogs with spontaneous
pulmonary metastases, Cancer 79:1409–1421, 1997.
eases, Expert Opin Biol Ther 5:817–832, 2005.
305. Dow S, Elmslie R, Kurzman I, et al.: Phase I study of liposome- 327. Coleman RE: Therapeutic use of bisphosphonates in oncology, Brit
DNA complexes encoding the interleukin-2 gene in dogs with Med J 309, 1994. 1233–1233.
osteosarcoma lung metastases, Hum Gene Ther 16:937–946, 2005. 328. Coleman RE, McCloskey EV: Bisphosphonates in oncology, Bone
306. Thamm DH, Kurzman ID, King I, et al.: Systemic administration 49:71–76, 2011.
of an attenuated, tumor-targeting Salmonella typhimurium to dogs 329. Carano A, Teitelbaum SL, Konsek JD, et al.: Bisphosphonates
with spontaneous neoplasia; phase I evaluation, Clin Cancer Res directly inhibit the bone resorption activity of isolated avian osteo-
11:4827–4834, 2005. clasts in vitro, J Clin Invest 85:456–461, 1990.
307. Goblirsch M, Mathews W, Lynch C, et al.: Radiation treatment 330. Hughes DE, Wright KR, Uy HL, et al.: Bisphosphonates promote
decreases bone cancer pain, osteolysis and tumor size, Radiat Res apoptosis in murine osteoclasts in vitro and in vivo, J Bone Miner
161:228–234, 2004. Res 10:1478–1487, 1995.
308. Withrow SJ, Powers BE, Straw RC, et al.: Tumor necrosis following 331. Luckman SP, Hughes DE, Coxon FP, et al.: Nitrogen-containing
radiation therapy and/or chemotherapy for canine osteosarcoma, bisphosphonates inhibit the mevalonate pathway and prevent post-
Chir Organi Mov 75:29–31, 1990. translational prenylation of GTP-binding proteins, including Ras,
309. Vakaet LA, Boterberg T: Pain control by ionizing radiation of bone J Bone Miner Res 13:581–589, 1998.
metastasis, Int J Dev Biol 48:599–606, 2004. 332. Tomlin JL, Sturgeon C, Pead MJ, et al.: Use of the bisphosphonate
310. Green EM, Adams WM, Forrest LJ: Four fraction palliative drug alendronate for palliative management of osteosarcoma in two
radiotherapy for osteosarcoma in 24 dogs, J Am Anim Hosp Assoc dogs, Vet Rec 147:129–132, 2000.
38:445–451, 2002. 333. Fan TM, de Lorimier LP, Charney SC, et al.: Evaluation of intra-
311. Knapp-Hoch HM, Fidel JL, Sellon RK, et al.: An expedited pal- venous pamidronate administration in 33 cancer-bearing dogs with
liative radiation protocol for lytic or proliferative lesions of appen- primary or secondary bone involvement, J Vet Intern Med 19:74–
dicular bone in dogs, J Am Anim Hosp Assoc 45:24–32, 2009. 80, 2005.
312. Mueller F, Poirier V, Melzer K, et al.: Palliative radiotherapy with 334. Fan TM, de Lorimier LP, O’Dell-Anderson K, et al.: Single-agent
electrons of appendicular osteosarcoma in 54 dogs, Vivo 19:713– pamidronate for palliative therapy of canine appendicular osteosar-
716, 2005. coma bone pain, J Vet Intern Med 21:431–439, 2007.
313. Ramirez 3rd O, Dodge RK, Page RL, et al.: Palliative radiotherapy 335. Tuohy J, Haussler K, Adrian C, et al.: Interim analysis of ran-
of appendicular osteosarcoma in 95 dogs, Vet Radiol Ultrasound domized placebo-controlled clinical trial of radiation therapy
40:517–522, 1999. +/- pamidronate for palliative treatment of canine appendicular
314. Mcentee MC, Page RL, Novotney CA, et al.: Palliative radiother- osteosarcoma, Vete Comp Oncol 9:e1–e49, 2011.
apy for canine appendicular osteosarcoma, Vet Radiol Ultrasound 336. Fan TM, Charney SC, de Lorimier LP, et al.: Double-blind
34:367–370, 1993. placebo-controlled trial of adjuvant pamidronate with palliative
315. Oblak ML, Boston SE, Higginson G, et al.: The impact of pami- radiotherapy and intravenous doxorubicin for canine appendicular
dronate and chemotherapy on survival times in dogs with appen- osteosarcoma bone pain, J Vet Intern Med 23:152–160, 2009.
dicular primary bone tumors treated with palliative radiation 337. Spugnini EP, Vincenzi B, Caruso G, et al.: Zoledronic acid for the
therapy, Vet Surg 41:430–435, 2012. treatment of appendicular osteosarcoma in a dog, J Small Anim
316. Holmes RA: [153Sm]EDTMP; a potential therapy for bone cancer Pract 50:44–46, 2009.
pain, Semin Nucl Med 22:41–45, 1992. 338. Fan TM, de Lorimier LP, Garrett LD, et al.: The bone biologic
317. Serafini AN: Samarium Sm-153 lexidronam for the palliation of effects of zoledronate in healthy dogs and dogs with malignant oste-
bone pain associated with metastases, Cancer 88:2934–2939, 2000. olysis, J Vet Intern Med 22:380–387, 2008.
318. Aas M, Moe L, Gamlem H, et al.: Internal radionuclide therapy 339. Lundberg AP, Roady PJ, Somrak AJ, et al.: Zoledronate-associated
of primary osteosarcoma in dogs, using 153Sm-ethylene-diamino- osteonecrosis of the jaw in a dog with appendicular osteosarcoma,
tetramethylene-phosphonate (EDTMP), Clin Cancer Res 5:3148s– J Vet Intern Med 30:1235–1240, 2016.
3152s, 1999. 340. Vail DM, MacEwen EG: Spontaneously occurring tumors of com-
319. Barnard SM, Zuber RM, Moore AS: Samarium Sm 153 lexidro- panion animals as models for human cancer, Cancer Invest 18:781–
nam for the palliative treatment of dogs with primary bone tumors; 792, 2000.
35 cases (1999-2005), J Am Vet Med Assoc 230:1877–1881, 2007. 341. Withrow SJ, Wilkins RM: Cross talk from pets to people; transla-
320. Lattimer JC, Corwin Jr LA, Stapleton J, et al.: Clinical and clini- tional osteosarcoma treatments, ILAR J 51:208–213, 2010.
copathologic response of canine bone tumor patients to treatment 342. Rowell JL, McCarthy DO, Alvarez CE: Dog models of naturally
with samarium-153-EDTMP, J Nucl Med 31:1316–1325, 1990. occurring cancer, Trends Mol Med 17:380–388, 2011.
321. Milner RJ, Dormehl I, Louw WK, et al.: Targeted radiotherapy 343. Ayerza MA, Farfalli GL, Aponte-Tinao L, et al.: Does increased
with Sm-153-EDTMP in nine cases of canine primary bone rate of limb-sparing surgery affect survival in osteosarcoma? Clin
tumours, J S Afr Vet Assoc 69:12–17, 1998. Orthop Relat Res 468:2854–2859, 2010.
322. Vancil JM, Henry CJ, Milner RJ, et al.: Use of samarium Sm 153 344. Mankin HJ, Hornicek FI, Rosenberg AE, et al.: Survival data for
lexidronam for the treatment of dogs with primary tumors of the skull; 648 patients with osteosarcoma treated at one institution, Clin
20 cases (1986-2006), J Am Vet Med Assoc 240:1310–1315, 2012. Orthop Relat Res 286–291, 2004.
323. Bryan JN, Bommarito D, Kim DY, et al.: Comparison of systemic 345. Marina NM, Smeland S, Bielack SS, et al.: Comparison of MAPIE
toxicities of 177Lu-DOTMP and 153Sm-EDTMP administered versus MAP in patients with a poor response to preoperative che-
intravenously at equivalent skeletal doses to normal dogs, J Nucl motherapy for newly diagnosed high-grade osteosarcoma (EURA-
Med Technol 37:45–52, 2009. MOS-1); an open-label, international, randomised controlled trial,
324. Chakraborty S, Balogh L, Das T, et al.: Evaluation of (1)(7)(7)Lu- Lancet Oncol 17:1396–1408, 2016.
EDTMP in dogs with spontaneous tumor involving bone; phar- 346. Okada K, Unni KK, Swee RG, et al.: High grade surface osteo-
macokinetics, dosimetry and therapeutic efficacy, Curr Radiopharm sarcoma - a clinicopathologic study of 46 cases, Cancer 85:1044–
9:64–70, 2016. 1054, 1999.